Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at UCLA Health

Sites in Los Angeles, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 10:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1106
Shown on this page
12
Current sort
Recently updated
Campus scope
UCLA Health, Los Angeles, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UCLA Health, Los Angeles, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 997–1008 of 1,106 matching trials with a site at UCLA Health, Los Angeles, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional

Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy

NCT06100887
Site status not listed — check the official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
6 Years to 17 Years · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Sacramento, California • Gainesville, Florida + 4 more
Active, not recruiting Phase 2 Interventional

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

NCT03539536
Site status not listed — check the official record
Conditions
Non-small Cell Lung Cancer
Interventions
Telisotuzumab vedotin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
56
States / cities
Mobile, Alabama • Phoenix, Arizona • Springdale, Arkansas + 49 more
Conditions
Fabry Disesase
Interventions
HM15421/GC1134A
Drug
Lead sponsor
GC Biopharma Corp
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Kansas City, Kansas • Minneapolis, Minnesota + 3 more
Recruiting Not applicable Interventional

Modernizing Perinatal Syphilis Testing

NCT06082453
Status at this site: Recruiting
Conditions
Syphilis
Interventions
Quantitative polymerase chain reaction (qPCR) assay for detection of Treponema pallidum, Aptima Treponema pallidum transcription-mediated amplification (TMA) assay for detection of Treponema pallidum, Center for Disease Control (CDC) Sexually Transmitted Infections (STI) 2021 Treatment Guidelines for diagnosis of syphilis
Diagnostic Test · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 45 Years
Enrollment
924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Baltimore, Maryland • Columbus, Ohio + 1 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

AMP SCZ® Observational Study: PREDICT-DPACC

NCT05905003
Site status not listed — check the official record
Conditions
Clinical High Risk, Psychosis, Remission, Conversion
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
12 Years to 30 Years
Enrollment
2,617 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
17
States / cities
Irvine, California • Los Angeles, California • San Diego, California + 13 more
Active, not recruiting Phase 4 Interventional

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

NCT03229200
Site status not listed — check the official record
Conditions
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease, Solid Tumor
Interventions
Ibrutinib
Drug
Lead sponsor
Pharmacyclics Switzerland GmbH
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
34
States / cities
Burbank, California • Duarte, California • La Jolla, California + 27 more
Active, not recruiting Phase 3 Interventional

A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia

NCT05515536
Site status not listed — check the official record
Conditions
Friedreich Ataxia
Interventions
Vatiquinone
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Tampa, Florida + 2 more
Conditions
Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer
Interventions
ABBV-400, Trifluridine/Tipiracil, Bevacizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
18
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 13 more
Conditions
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab soravtansine, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
35
States / cities
Tucson, Arizona • Fresno, California • Fullerton, California + 30 more
Conditions
Bladder Cancer
Interventions
N-803 and BCG, N-803
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
28
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Los Angeles, California + 25 more
Conditions
HIV Infections
Interventions
BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA, BG505 MD39.3 gp151 CD4KO mRNA
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 5 more
Active, not recruiting Phase 2 Interventional

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

NCT05384587
Site status not listed — check the official record
Conditions
Chronic Myelogenous Leukemia - Chronic Phase
Interventions
asciminib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
80
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 71 more

About this UCLA Health institution page

What this page lists
ClinicalTrials.gov records that list UCLA Health in Los Angeles, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.